comparemela.com

Kerry Wycislo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, in idiopat.

Rheinland pfalzKerry wycisloLos angelesToby maherBoehringer ingelheim pharmaceuticals incHuman pharma communicationsAnimal healthBoehringer ingelheimKeck school of medicineDrug administrationCorporate affairsOrphan drug designationClinical medicineKeck schoolBreakthrough therapyOrphan drug designations

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

InPedILD Phase III trial showed encouraging results for both primary endpoints. Full data were published in the European Respiratory Journal and presented at.

United statesComunidad autonoma de catalunaKerry wycisloRobin deterdingBoehringer ingelheimSusanne stowasserBoehringer ingelheim pharmaceuticalsBoehringer ingelheim pharmaceuticals incEuropean respiratory society international congressDrug administrationInternational congressEuropean respiratory societyHuman pharma communicationsAnimal healthEuropean medicines agencyCorporate affairs

vimarsana © 2020. All Rights Reserved.